Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.
TOT BIOPHARM International Co. Ltd. has announced the approval and implementation of new Terms of Reference for its Nomination Committee, effective July 1, 2025. The committee is tasked with reviewing the board’s structure, identifying qualified director candidates, and ensuring board diversity and independence. This move is expected to enhance the company’s governance and align its board composition with its strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. is a company incorporated in Hong Kong, operating within the biopharmaceutical industry. The company focuses on the development, manufacturing, and commercialization of oncology drugs, aiming to address the needs of cancer patients with innovative therapeutic solutions.
Average Trading Volume: 138,178
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.51B
Learn more about 1875 stock on TipRanks’ Stock Analysis page.